AMICUS THERAPEUTICS INC (FOLD) Stock Fundamental Analysis
NASDAQ:FOLD - Nasdaq - US03152W1099 - Common Stock - Currency: USD
We assign a fundamental rating of 4 out of 10 to FOLD. FOLD was compared to 553 industry peers in the Biotechnology industry. FOLD has an average financial health and profitability rating. FOLD has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
FOLD had negative earnings in the past year.
In the past year FOLD had a positive cash flow from operations.
FOLD had negative earnings in each of the past 5 years.
In the past 5 years FOLD always reported negative operating cash flow.
1.2 Ratios
FOLD has a Return On Assets of -3.72%. This is amongst the best in the industry. FOLD outperforms 88.07% of its industry peers.
FOLD has a better Return On Equity (-15.18%) than 87.34% of its industry peers.
FOLD has a better Return On Invested Capital (5.93%) than 93.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.72% | ||
| ROE | -15.18% | ||
| ROIC | 5.93% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Operating Margin value of 8.80%, FOLD belongs to the best of the industry, outperforming 93.49% of the companies in the same industry.
The Gross Margin of FOLD (90.60%) is better than 92.95% of its industry peers.
In the last couple of years the Gross Margin of FOLD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.8% | ||
| PM (TTM) | N/A | ||
| GM | 90.6% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so FOLD is destroying value.
FOLD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for FOLD has been increased compared to 5 years ago.
FOLD has a better debt/assets ratio than last year.
2.2 Solvency
FOLD has an Altman-Z score of -1.51. This is a bad value and indicates that FOLD is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of FOLD (-1.51) is comparable to the rest of the industry.
FOLD has a debt to FCF ratio of 242.98. This is a negative value and a sign of low solvency as FOLD would need 242.98 years to pay back of all of its debts.
FOLD's Debt to FCF ratio of 242.98 is amongst the best of the industry. FOLD outperforms 90.78% of its industry peers.
FOLD has a Debt/Equity ratio of 2.02. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of FOLD (2.02) is worse than 80.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.02 | ||
| Debt/FCF | 242.98 | ||
| Altman-Z | -1.51 |
ROIC/WACC0.58
WACC10.16%
2.3 Liquidity
A Current Ratio of 3.34 indicates that FOLD has no problem at all paying its short term obligations.
FOLD has a Current ratio of 3.34. This is in the lower half of the industry: FOLD underperforms 60.94% of its industry peers.
FOLD has a Quick Ratio of 2.47. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.47, FOLD is not doing good in the industry: 68.17% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.34 | ||
| Quick Ratio | 2.47 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 92.31% over the past year.
The Revenue has grown by 32.29% in the past year. This is a very strong growth!
FOLD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.73% yearly.
EPS 1Y (TTM)92.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%120%
Revenue 1Y (TTM)32.29%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%22.12%
3.2 Future
Based on estimates for the next years, FOLD will show a very strong growth in Earnings Per Share. The EPS will grow by 76.15% on average per year.
The Revenue is expected to grow by 19.94% on average over the next years. This is quite good.
EPS Next Y50.26%
EPS Next 2Y86.03%
EPS Next 3Y79.24%
EPS Next 5Y76.15%
Revenue Next Year17.91%
Revenue Next 2Y20.39%
Revenue Next 3Y20.66%
Revenue Next 5Y19.94%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
FOLD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 24.04, which indicates a rather expensive current valuation of FOLD.
91.68% of the companies in the same industry are more expensive than FOLD, based on the Price/Forward Earnings ratio.
FOLD's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 36.21.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 24.04 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of FOLD indicates a rather cheap valuation: FOLD is cheaper than 92.41% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, FOLD is valued cheaply inside the industry as 90.60% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 1210.27 | ||
| EV/EBITDA | 36.01 |
4.3 Compensation for Growth
FOLD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FOLD's earnings are expected to grow with 79.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y86.03%
EPS Next 3Y79.24%
5. Dividend
5.1 Amount
FOLD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.32
+0.33 (+5.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners94.99%
Inst Owner Change0.61%
Ins Owners0.6%
Ins Owner Change5.79%
Market Cap1.95B
Analysts82.22
Price Target15.98 (152.85%)
Short Float %7.71%
Short Ratio4.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)106.71%
Min EPS beat(2)-26.06%
Max EPS beat(2)239.47%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.23%
Min Revenue beat(2)-9.62%
Max Revenue beat(2)-0.84%
Revenue beat(4)2
Avg Revenue beat(4)-1.38%
Min Revenue beat(4)-9.62%
Max Revenue beat(4)2.52%
Revenue beat(8)4
Avg Revenue beat(8)-0.78%
Revenue beat(12)6
Avg Revenue beat(12)-1.43%
Revenue beat(16)8
Avg Revenue beat(16)-1.23%
PT rev (1m)0%
PT rev (3m)-6.19%
EPS NQ rev (1m)-7.07%
EPS NQ rev (3m)-1224.86%
EPS NY rev (1m)0%
EPS NY rev (3m)-372.44%
Revenue NQ rev (1m)-0.23%
Revenue NQ rev (3m)-2.19%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)-1.57%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 24.04 | ||
| P/S | 3.58 | ||
| P/FCF | 1210.27 | ||
| P/OCF | 546.35 | ||
| P/B | 10.05 | ||
| P/tB | N/A | ||
| EV/EBITDA | 36.01 |
EPS(TTM)-0.03
EYN/A
EPS(NY)0.26
Fwd EY4.16%
FCF(TTM)0.01
FCFY0.08%
OCF(TTM)0.01
OCFY0.18%
SpS1.76
BVpS0.63
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.72% | ||
| ROE | -15.18% | ||
| ROCE | 7.5% | ||
| ROIC | 5.93% | ||
| ROICexc | 9.77% | ||
| ROICexgc | 21.92% | ||
| OM | 8.8% | ||
| PM (TTM) | N/A | ||
| GM | 90.6% | ||
| FCFM | 0.3% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.02 | ||
| Debt/FCF | 242.98 | ||
| Debt/EBITDA | 6.97 | ||
| Cap/Depr | 23.74% | ||
| Cap/Sales | 0.36% | ||
| Interest Coverage | 0.82 | ||
| Cash Conversion | 6.36% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.34 | ||
| Quick Ratio | 2.47 | ||
| Altman-Z | -1.51 |
F-Score7
WACC10.16%
ROIC/WACC0.58
Cap/Depr(3y)68.89%
Cap/Depr(5y)61.13%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%120%
EPS Next Y50.26%
EPS Next 2Y86.03%
EPS Next 3Y79.24%
EPS Next 5Y76.15%
Revenue 1Y (TTM)32.29%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%22.12%
Revenue Next Year17.91%
Revenue Next 2Y20.39%
Revenue Next 3Y20.66%
Revenue Next 5Y19.94%
EBIT growth 1Y179.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year134.34%
EBIT Next 3Y110.27%
EBIT Next 5YN/A
FCF growth 1Y101.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y102.82%
OCF growth 3YN/A
OCF growth 5YN/A